Future options for the management of hepatitis C

Seminars in Liver Disease

Volumn 19, Issue 1 SUPPL. 1, 1999, Pages 103-112

  Davis, Gary L ^a   Nelson, David R ^a   Reyes, Gregory R ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Chemokines' cytokines; HCV helicase; HCV protease; HCV replicase; Ribozymes

Indexed keywords

ALPHA INTERFERON; CYTOKINE; HELICASE; NEUTRALIZING ANTIBODY; PROTEINASE; RIBAVIRIN; RIBOZYME; RNA DIRECTED DNA POLYMERASE;

DRUG EFFICACY; HEPATITIS C; HEPATITIS C VIRUS; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; LIVER INJURY; MOLECULAR MIMICRY; PRIORITY JOURNAL; REVIEW; VIRUS GENOME; VIRUS INHIBITION; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

EID: 0032925802     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492
2. Poynard T, Marcellin P, Lee S, et al. Randomised trial of interferon alfa-2b and ribavirin for 48 weeks or for 24 weeks versus Interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352: 1426-1432
3. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339: 1493-1499
4. Choo QL, Richman KH, Han JH, et al. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci U S A 1991;88:2451-2455
5. Iacovacci S, Sargiacomo M, Parolini I, Ponzetto A, Peschle C, Carloni G. Replication and multiplication of hepatitis C virus genome in human foetal liver cells. Res Virol 1993;144:275-279
6. Lanford RE, Sureau C, Jacob JR, White R, Fuerst TR. Demonstration of in vitro infection of chimpanzee hepatocytes with hepatitis C virus using strand-specific RT/PCR. Virology 1994;202:606-614
7. Yoo BJ, Selby MJ, Choe J, et al. Transfection of a differentiated human hepatoma cell line (Huh7) with in vitro-transcribed hepatitis C virus (HCV) RNA and establishment of a long-term culture persistently infected with HCV. J Virol 1995;69:32-38
8. Lau GK, Fang JW, Wu PC, Davis GL, Lau JY. Detection of hepatitis C virus genome in formalin-fixed paraffin-embedded liver tissue by in situ reverse transcription polymerase chain reaction. J Med Virol 1994;44:406-409
9. Kuo G, Choo QL, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989;244:362-364
10. Lau JYN, Davis GL. Detection of hepatitis C virus RNA genome in liver tissue by nonisotopic in situ hybridization. J Med Virol 1994;42:268-271
11. Fang JWS, Chow V, Lau JYN. Virology of the hepatitis C virus. Clinics in Liver Disease 1997;1:493-514
12. Hijikata M, Shimizu YK, Kato H, et al. Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes. J Virol 1993;67:1953-1958
13. Honda M, Ping LH, Rijnbrand RC, et al. Structural requirements for initiation of translation by internal ribosome entry within genome-length hepatitis C virus RNA. Virology 1996;222:31-42
14. Lo SY, Masiarz, F. Hwang SB, Lai MM, Ou JH. Differential subcellular localization of hepatitis C virus core gene products. Virology 1995;213:455-461
15. Kaito M, Watanabe S, Tsukiyama-Kohara K, et al. Hepatitis C virus particle detected by immunoelectron microscopic study. J Gen Virol 1994;75(pt 7):1755-1760
16. Bartenschlager R, Ahlborn-Laake L, Mous J, Jacobsen H. Non-structural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J Virol 1993;67:3835-3844
17. Grakoui A, McCourt DW, Wychowski C, Feinstone SM, Rice CM. Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites. J Virol 1993;67:2832-2843
18. Lin C, Thomson JA, Rice CM. A central region in the hepatitis C virus NS4A protein allows formation of an active NS3-NS4A serine proteinase complex in vivo and in vitro. J Virol 1995;69: 4373-4380
19. Suzich JA, Tamura JK, Palmer-Hill F, et al. Hepatitis C virus NS3 protein polynucleotide-stimulated nucleoside triphosphatase and comparison with the related pestivirus and flavivirus enzymes. J Virol 1993;67:6152-6158
20. Gonzalez-Peralta RP, Davis GL, Lau JY. Pathogenetic mechanisms of hepatocellular damage in chronic hepatitis C virus infection. J Hepatol 1994;21:255-259
21. Davis GL. Hepatitis C. In: Schiff ER, Maddrey W, Sorrel M, eds. Schiffs Diseases of the Liver. Philadelphia, Pa: Lippincott; 1998:793-836
22. Farci P, Orgiana G, Purcell RH. Immunity elicited by hepatitis C virus. Clin Exp Rheumatol 1995;13(suppl 13):S9-S12
23. Farci P, Alter HJ, Govindarajan S, et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992;258:135-140
24. Farci P, Alter HJ, Wong DC, et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci U S A 1994;91:7792-7796
25. Choo QL, Kuo G, Ralston R, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci U S A 1994;91:1294-1298
26. Krawczynski K, Alter MJ, Tankersley DL, et al. Effect of immune globulin on the prevention of experimental hepatitis C virus infection. J Infect Dis 1996;173:822-828
27. Esumi M, Ahmed M, Zhou YH, Takahashi H, Shikata T. Murine antibodies against E2 and hypervariable region 1 cross-reactively capture hepatitis C virus. Virology 1998;251: 158-164
28. Abrignani S, Rosa D. Perspectives for a hepatitis C virus vaccine. Clin Diagn Virol 1998;10:181-185
29. Armstrong SJ, Dimmock NJ. Neutralization of influenza virus by low concentrations of hemagglutinin-specific polymeric immunoglobulin A inhibits viral fusion activity, but activation of the ribonucleoprotein is also inhibited. J Virol 1992;66:3823-3832
30. Wickham TJ, Shuler ML, Hammer DA. A simple model to predict the effectiveness of molecules that block attachment of human rhinoviruses and other viruses. Biotechnol Prog 1995;11:164-170
31. Kim KH, Willingmann P, Gong ZX, et al. A comparison of the anti-rhinoviral drug binding pocket in HRV14 and HRV1A. J Mol Biol 1993;230:206-227
32. Rozhon E, Cox S, Buontempo P, et al. SCH 38057: a picornavirus capsid-binding molecule with antiviral activity after the initial stage of viral uncoating. Antiviral Res 1993;21:15-35
33. Wachsman MB, Castilla V, Coto CE. Inhibition of foot and mouth disease virus (FMDV) uncoating by a plant-derived peptide isolated from Melia azedarach L leaves. Arch Virol 1998;143:581-590
34. Singh IR, Suomalainen M, Varadarajan S, Garoff H, Helenius A. Multiple mechanisms for the inhibition of entry and uncoating of superinfecting Semliki Forest virus. Virology 1997;231:59-71
35. Reed KE, Rice CM. Expression and characterization of the HCV NS2 protease. In: Lau JY-N, ed. Hepatitis C Protocols. Totowa, NJ: Humana Press; 1998:331-342
36. Hijikata M, Mizushima H, Akagi T, et al. Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. J Virol 1993;67:4665-4675
37. Grakoui A, McCourt DW, Wychowski C, Feinstone SM, Rice CM. A second hepatitis C virus-encoded proteinase. Proc Natl Acad Sci U S A 1993;90:10583-10587
38. D'Souza EA, Gray N, Ellis M, Clarke BE. Expression and characterization of HCV NS3 protease. In: Lau JY-N, ed. Hepatitis C Protocols. Totowa, NJ: Humana Press: 1998:343-351
39. D'Souza ED, O'Sullivan E, Amphlett EM, Rowlands DJ, Sangar DV, Clarke BE. Analysis of NS3-mediated processing of the hepatitis C virus non-structural region in vitro. J Gen Virol 1994; 75(pt 12):3469-3476
40. Love RA, Parge HE, Wickersham JA, et al. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 1996;87:331-342
41. Kim JL, Morgenstern KA, Lin C, et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide [published erratum appears in Cell 1997 Apr 4;89(1):159].Cell 1996;87:343-355
42. Maison SW, Kaiser-Rogers KA. DNA helicases. Annu Rev Biochem 1990;59:289-329
43. Preugschat F, Averett DR, Clarke BE, Porter DJT. A steady-state and pre-steady-state kinetic analysis of the NTPase activity associated with the hepatitis C virus NS3 helicase domain. J Biol Chem 1996;271:24449-24457
44. Preugschat F, Hanlon MH, Rink MJ, Clarke BE, Porter DJT. Expression and characterization of the HCV NS3 helicase domain. In: Lau JY-N, ed. Hepatitis C Protocols. Totowa, NJ: Humana Press; 1998:353-364
45. Yao N, Hesson T, Cable M, et al. Structure of the hepatitis C virus RNA helicase domain. Nat Struct Biol 1997;4:463-467
46. Behrens SE, Tomei L, De Francesco R. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J 1996;15:12-22
47. von Weizsacker F, Wieland S, Kock J, et al. Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides, and dominant negative mutants. Hepatology 1997;26:251-255
48. Putnam DA. Antisense strategies and therapeutic applications [published erratum appears in Am J Health Syst Pharm 1996 Feb 1;53(3):325]. Am J Health Syst Pharm 1996;53:151-160
49. Lieber A, Strauss M. Selection of efficient cleavage sites in target RNAs by using a ribozyme expression library. Mol Cell Biol 1995;15:540-551
50. Welch PJ, Yei S, Barber JR. Ribozyme gene therapy for hepatitis C virus infection. Clin Diagn Virol 1998;10:163-171
51. Scaglioni P, Melegari M, Takahashi M, Chowdhury JR, Wands J. Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents. Hepatology 1996;24:1010-1017
52. Tsai SL, Liaw YF, Chen MH, Huang CY, Kuo GC. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 1997;25:449-458
53. Lee JH, Teuber G, Wagner MV, Roth WK, Zeuzem S. IL-12 in the treatment of chronic hepatitis C: effect on viremia and quasi-species distribution [abstract]. Hepatology 1998;24:472A. Abstract 1239
54. Teuber G, Berg T, Rodig S, Caspary WF, Hopf U, Zeuzem S. IL-12 therapy in patients with hepatitis C [abstract]. Gastroenterology 1998;114:A1354. Abstract L0638
55. Tilg H, Vogel W, Tratkiewicz J, et al. Pilot study of natural human interleukin-2 in patients with chronic hepatitis B. Immunomodulatory and antiviral effects. J Hepatol 1993;19:259-267
56. Pardo M, Castillo I, Oliva H, et al. A pilot study of recombinant interleukin-2 for treatment of chronic hepatitis C. Hepatology 1997;26:1318-1321
57. Abrignani S. Antigen-independent activation of resting T-cells in the liver of patients with chronic hepatitis. Dev Biol Stand 1998;92:191-194
58. Nelson DR, Marousis CG, Ohno T, Davis GL, Lau JY. Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C. Hepatology 1998;28:225-230
59. Napoli J, Bishop GA, McGuinness PH, Painter DM, McCaughan GW. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology 1996;24:759-765
60. Louis H, Van Laethem JL, Wu W, et al. Interleukin-10 controls neutrophilic infiltration, hepatocyte proliferation, and liver fibrosis induced by carbon tetrachloride in mice. Hepatology 1998;28:1607-1615
61. Cooper S, Erickson A, Chein D, et al. CTL directed against multiple hepatitis C viral proteins early in the course of infection correlate with immunity and endure following viral clearance. Presented at a US-Japan Joint Panel Meeting; 1998; Pacific Grove, CA
62. Takaki A, Wiese M, Maertens G, et al. A strong cellular, not humoral immune response distinguishes recovered from chronic patients 18 years after a single source outbreak of hepatitis C [abstract]. Hepatology 1998;28:320A. Abstract 630
63. Hu X, Chakraborty NG, Sporn JR, Kurtzman SH, Ergin MT, Mukherji B. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 1996;56:2479-2483
64. Caux C, Liu YJ, Banchereau J. Recent advances in the study of dendritic cells and follicular dendritic cells. Immunol Today 1995;16:2-4
65. Lau GK, Lok AS, Liang RH, et al. Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer. Hepatology 1997;25:1497-1501
66. Prezzi C, Nuzzo M, Meola A, et al. Selection of antigenic and immunogenic mimics of hepatitis C virus using sera from patients. J Immunol 1996;156:4504-4513
67. Encke J, zu Putlitz J, Geissler M, Wands JR. Genetic immunization generates cellular and humoral immune responses against the nonstructural proteins of the hepatitis C virus in a murine model. J Immunol 1998;161:4917-4923
68. Geissler M, Tokushige K, Wakita T, Zurawski VR Jr, Wands JR. Differential cellular and humoral immune responses to HCV core and HBV envelope proteins after genetic immunizations using chimeric constructs. Vaccine 1998;16:857-867
69. Lee SW, Cho JH, Lee KJ, Sung YC. Hepatitis C virus envelope DNA-based immunization elicits humoral and cellular immune responses. Mol Cells 1998;8:444-451
70. Sarobe P, Pendleton CD, Akatsuka T, et al. Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions. J Clin Invest 1998;102:1239-1248
71. Wong C, Morse M, Nair SK. Induction of primary, human antigen-specific cytotoxic T lymphocytes in vitro using dendritic cells pulsed with peptides. J Immunother 1998;21:32-40
72. Stephenson J. Defective adenoviruses as novel vaccines for the Flaviviridae. Clin Diagn Virol 1998;10:187-194
73. Morland CM, Shields PL, Adams DH. Human sinusoidal endothelial cells secrete IP-10 & RANTES: a mechanism for selective recruitment of activated memory T cells to the inflamed liver [abstract]. Hepatology 1998;28:255A. Abstract 371
74. Lau JY, Bird GL, Naoumov NV, Williams R. Hepatic HLA antigen display in chronic hepatitis B virus infection. Relation to hepatic expression of HBV genome/gene products and liver histology. Dig Dis Sci 1993;38:888-895
75. Shimizu Y, Guidotti LG, Fowler P, Chisari FV. Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice. J Immunol 1998;161:4520-4529